PKTX.. Possible gold Mine..? With Protokinetix(PKTX) supplying in an agreement their molecule...AAGP. To the Umbra Applied Technologies Group..This could be a fast track protocol with the military and using some university laboratories.. ….Blood storage and platelet preservation is a major issue. Every day in the U.S., approximately 41,000 units of blood are required in hospitals and emergency treatment facilities for patients needing treatment with cancer, organ transplants, and accident/trauma. There is a constant, vital demand for greater blood supply and storage management. Chuck Winters further stated that, "The aim of Propestat is to increase the viability of blood products and platelets. We believe that Propestat has the potential to help doctors save the lives of their patients by creating a better, more stable supply of blood and blood platelets." Chairman of Umbra Applied Technologies Group, Alex Umbra, remarked that "We are truly excited about the future of Propestat and look forward to undergoing preclinical trials in the near future". Propestat was developed under exclusive agreement with Protokinetix , Umbra Applied Technologies Group anticipates that its continued collaboration with Protokinetix will ensure that Propestat impacts the biotechnology community, and ultimately, patients in a very meaningful way." ….Umbra Applied Technologies Group (OTC: UATG) announces that its Biotech Division has finalized agreements that will enable the Company(UTA) to bring forward the greatly anticipated blood preservation treatment Propestat™. Propestat™ is the backbone of UAT's Cellgevity™ brand found only in the much-anticipated Blood Management System. ….Under Project Ichor, UAT worked closely with its sister company, Intrepid Medical Technologies Corporation to deliver the UAT BMS (Blood Management System). With this new Blood Management System, UAT introduces a paradigm shift in blood management with an advanced, reliable and cost-efficient blood and platelet containment system design. When released, the UAT blood management system with Cellgevity™ powered by UAT's Propestat™ will be the most technologically advanced blood collection and storage system in the world. UAT's blood and platelet management system offers outstanding preservation performance with an unparalleled attention to function, ergonomics and quality. When asked about the collaboration among the subsidiary companies of UAT Group, CEO of Intrepid Innovations Corporation Chuck Winters, responded, "The dynamic among all of our subsidiaries is one of absolute cooperation because we are all one family working towards a common and clearly defined goal." UAT's blood management system with Cellgevity™ will deliver unparalleled performance preserving blood platelets up to 10 times longer than any other bag in the world. This revolutionary new Blood Management System is just that, a system of sophisticated technology working harmoniously together to document historical information on its contents and extend viability and integrity of blood products. Whole blood and whole blood products are obtained directly or indirectly through blood donation from which no constituent like red blood cells, white blood cells, plasma, or platelets, are removed. Whole blood management has not seen much improvement as 90% of blood collected globally uses a manual process that includes record keeping, handling, and transportation. This provides significant opportunity for Umbra Applied Technologies, which is working towards the improvement of existing protocols and preservation technology. Umbra Applied Technologies (UAT) Chief Executive Officer Alex Umbra, was quoted as saying, "UAT's Biotech segment will prove to be a long-term growth driver for the company because of its acquisition strategies and commitment to advancing technology in this segment." When speaking with Mr. Umbra, he was very optimistic about biotech and cited a few of the reasons why he feels biotech is a good investment for a company to make; "If you take a look at the biotechnology industry, you will notice that it was adversely affected by the global financial crisis, with several leading biotechnology companies in the US and Europe reporting fall in revenues amid restricted capital inflows, and project cancellations and delays. The industry however recovered strongly from the crisis with a number of major biotechnology companies registering profits largely due to the adoption of new efficiency and cost-saving measures. This is indicative of how well we in the industry adopt and innovate." Mr. Umbra further elaborated when he was quoted as saying, "According to analysts, there are many indicators that the global biotechnology market will surpass US$320 Billion by 2015, and this represents a significant opportunity for growth in our biotech market segment." "We are very excited to bring Propestat™ to market in the near term," said Mr. Umbra. "A small portion of the global biotechnology market that just includes global blood processing products and consumables market revenue is expected to grow at a CAGR of 8.9% over the next six years, to reach a market worth $49.16 billion in 2019, and the Propestat™ brand will be the only product to offer improved efficacy and assure a never-before-seen level of viability."
-------------------- The check is in the mail... Posts: 138 | From: Florida | Registered: Dec 2009
| IP: Logged |